Vulvar and vaginal melanoma: Case series and review of current management options including neoadjuvant chemotherapy
| Autor: | William A. Cliby, Amy L. Weaver, Svetomir N. Markovic, Jo Marie Tran Janco |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Vaginal Neoplasms Paclitaxel Bevacizumab medicine.medical_treatment Carboplatin chemistry.chemical_compound Antineoplastic Combined Chemotherapy Protocols Temozolomide medicine Adjuvant therapy Humans Melanoma Survival rate Neoadjuvant therapy Vulvar Neoplasms business.industry Vulvectomy Obstetrics and Gynecology Neoadjuvant Therapy Surgery Dacarbazine Survival Rate Treatment Outcome Oncology chemistry Chemotherapy Adjuvant Lymphatic Metastasis Female Vaginal Melanoma Lymphadenectomy business medicine.drug |
| Zdroj: | Gynecologic Oncology. 129:533-537 |
| ISSN: | 0090-8258 |
| DOI: | 10.1016/j.ygyno.2013.02.028 |
| Popis: | Objective We report our experience with vulvar (Vu) and vaginal (Va) melanoma, with review of surgical and adjuvant therapy guidelines and description of our use of neoadjuvant therapy in selected cases. Methods We reviewed patients seen at Mayo Clinic for management of Vu or Va melanoma, January 1993–February 2012. Surgical treatment, pathologic and outcome data were abstracted. Overall survival (OS) and recurrence-free survival (RFS) were estimated using the Kaplan–Meier method, and compared between subgroups using the log-rank test. Results 50 patients underwent surgery for primary or recurrent melanoma (Vu=36, Va=14). The 5-year OS rate was 30.9%, with median OS of 3.3years. Adjuvant therapy was given to 30.6% of Vu cases with varying combinations of agents. Among Vu patients, after adjusting for node status and depth of invasion, adjuvant therapy was not associated with improved OS (p=0.39) or RFS (p=0.31). Preoperative chemotherapy was used in 2 Va cases. Despite temozolomide followed by exenteration for a 4cm multi-focal lesion, one patient died within 3months. The second patient, with a 2cm vaginal lesion, demonstrated a partial response to carboplatin and paclitaxel (CP). After local excision and lymphadenectomy she received additional CP with bevacizumab and remains disease free at 5years. CP with bevacizumab was also used in 1 Vu case with a solitary 5cm midline lesion. She underwent vulvectomy after a partial response, received additional CP and bevacizumab postoperatively, and remains without disease at 2years. Conclusion Preoperative chemotherapy with CP and bevacizumab may improve treatment outcomes, particularly for Va and large Vu lesions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect